Sandoz Aims to Amend Validity Ruling In Pfizer's Toviaz Suit
Several drug companies including Sandoz Inc. want a Delaware federal judge to amend his judgment directed after a trial that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz is...To view the full article, register now.
Already a subscriber? Click here to view full article